Concepedia

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Linghua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George W. Muller, Peter Schäfer, David Stirling,

Microvascular Research · 2005 · 268 citations · 19 references

DOI

Concepts

References

19

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

, , +14

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations

, , +14

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, Robert Schlossman, Edie Weller et al. · Blood · 2002 · 804 citations · Full text

, , +12

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

British Journal of Cancer · 1998 · 654 citations · Full text

, , +10

Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner

Yasushi Fujio, Kenneth Walsh · Journal of Biological Chemistry · 1999 · 555 citations · Full text

, , +15